Estrella Immunopharma
Business Services · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
5858 Horton St Ste 170, Emeryville, Cali...Phone Number
(510) 318-9098Website
www.estrellabio.comRevenue
<$5 MillionStock Symbol
ESLAIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Estrella Immunopharma
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.Explore more
Popular SearchesEstrella Immunopharma IncEstrella Biopharma IncEstrella BiopharmaSIC Code 87,873NAICS Code 54,541Ticker NASDAQ: ESLAShow more
Estrella Immunopharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Estrella Immunopharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Estrella Immunopharma had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Estrella Immunopharma
Funding: Get notified immidiatlly once Estrella Immunopharma has new funding data
Earning: See what the market has to say on Estrella Immunopharma recently announced quarterly report
Estrella Immunopharma, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Estrella Immunopharma launches new products
Check if Estrella Immunopharma has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Check out if Estrella Immunopharma is spiking on competitors!
Recommended Actions
Find VP level buyers at Estrella Immunopharma
Find more new buyers
Compare Similar Companies to Estrella Immunopharma
Compare insights from companies similar to Estrella Immunopharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Estrella Immunopharma is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Estrella Immunopharma is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Estrella Immunopharma.
Estrella Immunopharma financials insights
Gather financial insights about Estrella Immunopharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Stock/Share Issuance
$3.4M
Estrella Immunopharma Tech Stack
Most Recent Scoops
Funding
Funding
Earnings
Clinical Operations, Operations, Regulations
Earnings
Earnings
Finance, Risk
Earnings
Project
Partnership, Engineering, Product Development, Software, Clinical Operations, Healthcare Technology, Operations
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Estrella Immunopharma
Sign Up For FreeTo access detailed company insights
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute... Read More
